Patents Assigned to HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF—INSTITUTE OF RADIOPHARMACEUTICAL CANCER RESEARCH
  • Patent number: 11353460
    Abstract: This invention provides an antibody or functional antibody fragments, or probe thereof directed against a unique group of antigens identified in cancer. The present invention comprises nucleotide sequences derived from L2A5 monoclonal antibody. The antibody or functional antibody fragment, or probe thereof includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. This DNA/amino acid sequence conjugation is unique and has never been described before. The present invention further provides antibody or functional antibody fragment or a conjugate or a recombinant protein useful in the detection, treatment and prevention of human disease, including cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: June 7, 2022
    Assignees: UNIVERSIDADE NOVA DE LISBOA, INSTITUTO PORTUGUÊS DE ONCOLOGIA DO PORTO FG, EPE, HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF—INSTITUTE OF RADIOPHARMACEUTICAL CANCER RESEARCH
    Inventors: Paula Alexandra Quintela Videira, Carlos Manuel Mendes Novo, Liliana Raquel Rodrigues Loureiro, Mylène Adelaide do Rosário Carrascal, José Alexandre Ribeiro de Castro Ferreira, Maria Angelina de Sá Palma, Lúcio Lara Santos, Luís Carlos Oliveira Lima, Wengang Chai, Michael Bachmann